Socioeconomic Factors Increase Risk for Age-Related Macular Degeneration

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 25, 2024.

By Lori Solomon HealthDay Reporter

WEDNESDAY, Sept. 25, 2024 -- Socioeconomic factors are linked to an increased risk for age-related macular degeneration (AMD), according to a study published online July 1 in Health Data Science.

Yanlin Qu, from the Shanghai Jiao Tong University School of Medicine, and colleagues investigated whether low socioeconomic status (SES) increases the risk for AMD and explored the effect of a healthy lifestyle on this association. The analysis included data from 316,663 participants in the U.K. Biobank.

The researchers found that during an average 12.2 years of follow-up, 6,355 AMD cases were diagnosed. There was an increased risk for incident AMD among participants with medium SES (hazard ratio, 1.10) and low SES (hazard ratio, 1.22) compared with participants with high SES. This association was significantly affected by physical activity. Smoking also significantly mediated the association between low SES and AMD (11.3 percent). Alcohol consumption suppressed (9.59 percent) the association between high SES and AMD. A significant joint effect of SES and healthy lifestyle score was found.

"Our study identified a significant association between SES inequality and the incidence of AMD. Notably, the relationship was influenced by lifestyle behaviors," lead author Huixun Jia, from Shanghai General Hospital, said in a statement. "Our findings underscore the universal benefits of positive lifestyle adjustments. Encouraging physical activity and smoking cessation among individuals with low SES, and reducing alcohol consumption among high SES groups, could mitigate their susceptibility to AMD."

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Posted September 2024

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Recently Approved

Emrelis
Emrelis (telisotuzumab vedotin) is a first-in-class, c-Met protein directed...
Avmapki Fakzynja Co-Pack
Avmapki Fakzynja Co-Pack (avutometinib and defactinib, co-packaged) is a kinase...
Atzumi
Atzumi (dihydroergotamine mesylate) is a nasal powder formulation of the...

More drug approvals

AAP Updates Guidelines for Pediatric Atopic Dermatitis Management

MRI-Guided Biopsy Linked to Durability of Active Surveillance in Prostate Cancer

Wearable Sensor Can Monitor Sleep Apnea Treatment Response